Clinical Trial Update: JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update on a JAK1 inhibitor combined with medicated topical therapy for adolescents with atopic dermatitis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• JAK1 inhibitor (unspecified in provided data)
• Medicated topical therapy

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2021-06-04